MREO
Mereo BioPharma Group plc
NASDAQ · Healthcare · Biotechnology · GB
$0.25
−8.16%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +31.2%
- EBIT
- +26.0%
- EPS
- +42.6%
- Free cash flow
- +23.7%
- Operating cash flow
- +23.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +76.9%
- EPS
- +61.1%
Three-year CAGR
- Revenue
- -77.6%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +7.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026